Effects of dietary microalgae on growth, survival and fatty acid composition of sea urchin Paracentrotus lividus throughout larval development

This study investigated the growth, survival and fatty acid composition of sea urchin Paracentrotus lividus larvae fed four microalgal diets: Cricosphaera elongata, Pleurochrysis carterae, Tetraselmis suecica and Dunaliella tertiolecta (control). Larvae were successfully raised to competence for metamorphosis when fed C. elongata, P. carterae and D. tertiolecta diets but significant differences were found in survival rate and development. Larvae fed C. elongata showed 3 times higher survival and 20 % faster development than larvae fed the other two microalgae diets that supported development. In contrast, T. suecica failed to fully support development and larvae stalled at the four arms stage for more than 30 days. The urchin larvae could accumulate long-chain polyunsaturated fatty acids (LC-PUFA) such as docosahexaenoate (DHA; 22:6n-3), eicosapentaenoate (EPA; 20:5n-3) and arachidonate (ARA; 20:4n-6), either by assimilation and retention of dietary fatty acids, and/or synthesis from α-linolenic acid 18:3n-3 and linoleic acid 18:2n-6. Moreover, an accumulation of n-3 LC-PUFA and higher EPA/DHA and EPA/ARA ratios appeared to be associated with improved larval performance. The results indicate that live microalgae species, with appropriate fatty acid profiles are able to improve P. lividus larval performance, ultimately increasing hatchery profitability

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations predicting response or survival. We analyzed a retrospective multi-center cohort of 174 CMML patients treated with a median of 7 cycles of azacitidine (n = 68) or decitabine (n = 106). Sequencing data before treatment initiation were available for all patients, from Sanger (n = 68) or next generation (n = 106) sequencing. Overall response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%). In multivariate analysis, ASXL1 mutations predicted a lower ORR (Odds Ratio [OR] = 0.85, p = 0.037), whereas TET2mut/ASXL1wt genotype predicted a higher CR rate (OR = 1.18, p = 0.011) independently of clinical parameters. With a median follow-up of 36.7 months, overall survival (OS) was 23.0 months. In multivariate analysis, RUNX1mut (Hazard Ratio [HR] = 2.00, p = .011), CBLmut (HR = 1.90, p = 0.03) genotypes and higher WBC (log10(WBC) HR = 2.30, p = .005) independently predicted worse OS while the TET2mut/ASXL1wt predicted better OS (HR = 0.60, p = 0.05). CMML-specific scores CPSS and GFM had limited predictive power. Our results stress the need for robust biomarkers of HMA activity in CMML and for novel treatment strategies in patients with myeloproliferative features and RUNX1 mutations. Keywords: Chronic myelomonocytic leukemia, Hypomethylating agents, Somatic mutations, Prognosi

Porcine circovirus type 2 (PCV2)-infection and re-inoculation with homologous or heterologous strains: virological, serological, pathological and clinical effects in growing pigs.

Long-term PCV2 infection and/or concurrent infection with genotypes PCV2a and PCV2b may play a role in the development of clinical porcine circovirus-associated disease (PCVAD). To evaluate this premise, 24 11-week-old specific pathogen-free (SPF) pigs were randomly assigned to 1 of 4 treatments: negative controls, a single inoculation with PCV2a, single inoculation followed by re-inoculation with a homologous PCV2a strain, or repeated inoculations with heterologous strains (PCV2a, PCV2b). Pigs were evaluated for clinical signs daily through 140 days post inoculation (dpi). Serum samples were collected every other day from dpi 0 through 14 and weekly thereafter. PCV2-inoculated pigs were viremic by dpi 2 and 13 of 18 pigs remained viremic at 140 dpi. No statistical differences in the onset, level, or duration of PCV2 viremia were detected among treatment groups. Anti-PCV2 antibodies were detected between 14 and 28 dpi and were present through 140 dpi without statistical differences in antibody response among treatment groups. In the current study, pigs had extended viremia combined with detectable tissue PCV2 antigen levels despite the presence of high levels of anti-PCV2 antibody; however, no clinical disease was observed